Handelsbanken Fonder AB lowered its position in Zai Lab Limited (NASDAQ:ZLAB – Free Report) by 27.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 68,685 shares of the company’s stock after selling 25,900 shares during the period. Handelsbanken Fonder AB owned approximately 0.07% of Zai Lab worth $1,877,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of the company. Bamco Inc. NY boosted its position in Zai Lab by 4.5% in the third quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock valued at $38,394,000 after buying an additional 67,288 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Zai Lab by 1.2% in the third quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock valued at $30,072,000 after buying an additional 14,600 shares during the last quarter. Clearbridge Investments LLC boosted its position in Zai Lab by 1.4% in the third quarter. Clearbridge Investments LLC now owns 822,888 shares of the company’s stock valued at $20,004,000 after buying an additional 11,574 shares during the last quarter. Vivo Capital LLC boosted its position in Zai Lab by 2.0% in the third quarter. Vivo Capital LLC now owns 454,606 shares of the company’s stock valued at $11,051,000 after buying an additional 9,101 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its position in Zai Lab by 251.1% in the third quarter. Hsbc Holdings PLC now owns 327,781 shares of the company’s stock valued at $7,968,000 after buying an additional 234,431 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.
Insider Activity
In other news, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the transaction, the insider now owns 28,684 shares in the company, valued at approximately $449,478.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Ying Du sold 5,787 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $16.15, for a total transaction of $93,460.05. Following the transaction, the chief executive officer now owns 1,107,972 shares in the company, valued at approximately $17,893,747.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua L. Smiley sold 1,988 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total value of $31,151.96. Following the completion of the transaction, the insider now directly owns 28,684 shares of the company’s stock, valued at $449,478.28. The disclosure for this sale can be found here. Insiders have sold 12,568 shares of company stock worth $208,508 in the last quarter. Corporate insiders own 5.23% of the company’s stock.
Zai Lab Stock Performance
Zai Lab (NASDAQ:ZLAB – Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The business had revenue of $65.83 million for the quarter, compared to analysts’ expectations of $70.41 million. As a group, equities research analysts expect that Zai Lab Limited will post -3.27 earnings per share for the current year.
Analyst Ratings Changes
ZLAB has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Friday, January 12th. Citigroup lowered their price objective on Zai Lab from $123.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $64.22.
View Our Latest Stock Analysis on Zai Lab
Zai Lab Company Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Stories
- Five stocks we like better than Zai Lab
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Shanghai Stock Exchange Composite Index?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Limited (NASDAQ:ZLAB – Free Report).
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.